BioWorld-International-2010-06-09

No Abstract

No Abstract

Six months after acquiring the Humalex antibody platform from Humalys, Vivalis SA secured its first license agreement for the technology, a wide-ranging alliance in infectious disease with Paris-based Sanofi-Aventis Group. Nantes, France-based Vivalis is receiving an up-front payment of €3 million (US$3.6 million), plus another potential €35 million in milestones per indication, as well as royalties on product sales. (BioWorld International)

No Abstract

No Abstract

No Abstract